Abstracts tagged "cutaneous lupus"

Abstract Number: 1775 • 2015 ACR/ARHP Annual Meeting
Fn14 Deficiency Protects Lupus-Prone Mice from Cutaneous Lesions Induced By Ultraviolet B (UVB) Irradiation
Jessica Doerner¹, Adam Friedman², Linda Burkly³ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Department of Dermatology, George Washington School of Medicine and Health Sciences, Washington, DC, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Sunlight, via ultraviolet B (UVB) irradiation, is a well-recognized trigger of cutaneous lupus erythematosus (CLE) skin lesions. TNF-like weak inducer of apoptosis (TWEAK), a…
Abstract Number: 799 • 2015 ACR/ARHP Annual Meeting
Transcriptional Profiling of Cutaneous Lupus Reveals Pronounced Changes in Keratinocyte and Myeloid Lineage Expressed Genes and Demonstrates Uniquely Regulated Interferon Pathways Between Rash Subtypes
Celine C. Berthier¹, Jasmine Stannard², Emily Myers³, William Swindell⁴, Lori Lowe⁴, Tamra J. Reed⁵, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁶, ¹Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ²Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, Georgetown University, Washington, DC, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus rashes can be substantial, disfiguring, and often refractory to usual lupus therapies. Phenotypic presentation and risk of systemic lupus manifestations differs by…
Abstract Number: 861 • 2014 ACR/ARHP Annual Meeting
Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus
Clayton Sontheimer¹ and Keith B. Elkon², ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose Photosensitivity is a common symptom in patients with systemic lupus erythematosus (SLE) and lupus skin lesions often contain plasmacytoid dendritic cells (pDC). The mechanisms…
Abstract Number: 641 • 2014 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase Inhibition Mitigates NET Formation and Protects Against Kidney, Skin, and Vascular Disease in Lupus-Prone MRL/Lpr Mice
Jason S. Knight¹, Venkataraman Subramanian², Alexander A. O'Dell¹, Srilakshmi Yalavarthi¹, Wenpu Zhao³, Carolyne K. Smith³, Jeffrey B. Hodgin⁴, Paul Thompson² and Mariana J. Kaplan³, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²The Scripps Research Institute, Jupiter, FL, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Department of Pathology, University of Michigan, Ann Arbor, MI
Background/Purpose: An imbalance between neutrophil extracellular trap (NET) production and NET degradation has been observed in systemic lupus erythematosus (SLE), potentially contributing to autoantigen externalization,…
Abstract Number: 1860 • 2013 ACR/ARHP Annual Meeting
Novel Proinflammatory Microvesicles That Carry LL-37 In Patients With Cutaneous Lupus
Ming-Lin Liu^1,2,3, Muhammad Bashir^1,4, Meena Sharma^1,4, Honghui Xu^1,4, Kevin Williams³, Cynthia O. Anyanwu^4,5, Joyce Okawa^1,6 and Victoria P. Werth^1,4, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology,, Philadelphia V.A. Hospital, Philadelphia, PA, ³Department of Medicine, Temple University School of Medicine, Philadelphia, PA, ⁴Department of Dermatology, Philadelphia V.A. Hospital, Philadelphia, PA, ⁵Department of Dermatology, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ⁶Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) refers to variants of lupus erythematosus (LE) with exclusively or predominantly skin manifestations. CLE is associated with accumulation of autoantibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].